NUWE vs NVCR vs ANGO vs ATRC vs CNMD

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -5. 4% for Nuwellis, Inc. (NUWE). CONMED Corporation (CNMD) offers the better valuation at 25. 2x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, CONMED Corporation is actually cheaper at 8.

7x.

Over the past 5 years, AngioDynamics, Inc.

(ANGO) delivered a total return of -53. 3%, compared to -100. 0% for Nuwellis, Inc. (NUWE). Over 10 years, the gap is even starker: ATRC returned +95. 1% versus NUWE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AtriCure, Inc.

(ATRC) is the lower-risk stock at 1. 03β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 115% more volatile than ATRC relative to the S&P 500. On balance sheet safety, Nuwellis, Inc. (NUWE) carries a lower debt/equity ratio of 13% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -5. 4% for Nuwellis, Inc. (NUWE). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -217. 4% for Nuwellis, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CONMED Corporation (CNMD) is the more profitable company, earning 3.

4% net margin versus -211. 8% for Nuwellis, Inc. — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNMD leads at 10. 3% versus -134. 3% for NUWE. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CONMED Corporation (CNMD) trades at 8.

7x forward P/E versus 370. 7x for AtriCure, Inc. — 362. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNMD: 104. 8% to $78. 00.

In this comparison, CNMD (2.

1% yield) pays a dividend. NUWE, NVCR, ANGO, ATRC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CONMED Corporation (CNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2.

1% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNMD: +6. 6%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

CNMD pays a dividend while NUWE, NVCR, ANGO, ATRC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.